2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-183646
    Nav1.8-IN-23
    		Inhibitor
    Nav1.8-IN-23 is a Nav1.8 voltage-gated sodium channel inhibitor with a pIC50 of 6.1. Nav1.8-IN-23 can be used for the research of pain-related diseases.
    Nav1.8-IN-23
  • HY-175289
    hERG-IN-3
    		Inhibitor
    hERG-IN-3 is an orally active hERG blocker with an IC50 of 44.5 nM. hERG-IN-3 exhibits a Ki for β2-adrenergic receptor of 14 nM. hERG-IN-3 exhibits the skeletal muscle Nav1.4 and sodium channel-blocking activities (IC50 = 4.4 μM, 3-fold increasement than hNav1.5). hERG-IN-3 displays a potent antimyotonic activity in an animal model. hERG-IN-3 can be used for the study of Myotonia Congenita.
    hERG-IN-3
  • HY-135495
    AM-0466
    		Inhibitor
    AM-0466 is a sodium channel inhibitor with nanomolar levels of NaV1.7 inhibitory activity. AM-0466 exhibits potent pharmacodynamic activity in a NaV1.7-dependent histamine-induced itch model. AM-0466 also showed significant analgesic effects in capsaicin-induced pain models. After optimizing its pharmacokinetic properties, AM-0466 was advanced into in vivo targeting and efficacy models for testing.
    AM-0466
  • HY-N2026AR
    Propylparaben sodium (Standard)
    		Inhibitor
    Propylparaben (Propyl parahydroxybenzoate) sodium (Standard) is the analytical standard of Propylparaben sodium (HY-N2026A). Propylparaben (Propyl parahydroxybenzoate) sodium is an antibacterial preservative that can be produced by plants and bacteria. Propylparaben sodium is an orally active weak estrogen receptor agonist. Propylparaben sodium regulates the PI3K-AKT and JNK signaling pathways, and induces oxidative stress. Propylparaben sodium is commonly used in cosmetics, pharmaceuticals and foods, and can be used in studies related to ovarian aging and myocardial ischemia-reperfusion injury.
    Propylparaben sodium (Standard)
  • HY-W415121R
    Bupivacaine hydrochloride monohydrate (Standard)
    		Inhibitor
    Bupivacaine (hydrochloride monohydrate) (Standard) is the analytical standard of Bupivacaine (hydrochloride monohydrate). This product is intended for research and analytical applications. Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain.
    Bupivacaine hydrochloride monohydrate (Standard)
  • HY-B0161CR
    (R)-Duloxetine (Standard)
    		Inhibitor
    (R)-Duloxetine (Standard) is the analytical standard of (R)-Duloxetine. This product is intended for research and analytical applications. (R)-Duloxetine is a form of Duloxetine (HY-B0161) that causes tonic and usage-dependent impairment of neuronal Na+ channels. (R)-Duloxetine can be used in pain research.
    (R)-Duloxetine (Standard)
  • HY-121535
    Levosemotiadil
    		Inhibitor
    Levosemotiadil, an S-isomer of semotiadil, exhibits stronger binding affinity to human serum albumin (HSA) compared to its R-isomer counterpart. This study utilized high-performance frontal analysis (HPFA) to demonstrate that levosemotiadil binds approximately three times more strongly to HSA than semotiadil. The binding parameters were evaluated using Scatchard analysis, revealing specific interactions with the diazepam binding site on HSA. The presence of diazepam decreased the binding affinity of both enantiomers, while warfarin did not alter their binding characteristics. These findings highlight levosemotiadil's potential as a Ca- and Na-channel blocker with significant binding preferences for HSA, crucial for understanding its pharmacokinetics and therapeutic effects.
    Levosemotiadil
  • HY-Z8176
    (Z)-Flunarizine
    		Inhibitor
    (Z)-Flunarizine is the (Z)-isomer of Flunarizine (HY-B0358). Flunarizine is a potent dual Na+/Ca2+ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects.
    (Z)-Flunarizine
  • HY-111245
    AZD-1305
    		Inhibitor
    AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research.
    AZD-1305
  • HY-174845
    Nav1.8-IN-20
    		Inhibitor
    Nav1.8-IN-20 (Compound I) is an orally active and potent voltage-gated sodium channel Nav1.8 inhibitor with an IC50 value of 14 nM. Nav1.8-IN-20 blocks the generation and conduction of action potentials in peripheral nociceptive neurons, exerting analgesic effects. Nav1.8-IN-20 is promising for research of various pain types such as acute pain, chronic pain, inflammatory pain, and neuropathic pain.
    Nav1.8-IN-20
  • HY-115359
    BL-1021
    		Inhibitor
    BL-1021 is an orally active ion channel blocker. BL-1021 significantly reduces symptoms of neuropathic pain without noticeable sedation or cardiac arrhythmias. BL-1021 can be used in the research of acute and chronic pain.
    BL-1021
  • HY-184190
    ERG-IN-7
    		Inhibitor
    ERG-IN-7 is a Nav1.5, Cav1.2 and Kv11.1 inhibitor with IC50 values of 10.34 μM, 21.01 μM, and 16.385 μM for human Nav1.5, Cav1.2, and Kv11.1, respectively. ERG-IN-7 prolongs action potentials, reduces conduction velocity, and restores cardiac function. ERG-IN-7 can be used for the research of ventricular arrhythmia.
    ERG-IN-7
  • HY-P5942
    Pterinotoxin-2
    		Inhibitor
    Pterinotoxin-2 is a sodium channel inhibitor peptide toxin.
    Pterinotoxin-2
  • HY-B0703S
    Eslicarbazepine acetate-d4
    		Inhibitor
    Eslicarbazepine acetate-d4 is deuterated labeled Eslicarbazepine acetate (HY-B0703). Eslicarbazepine acetate (BIA 2-093), an antiepileptic agent, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel.
    Eslicarbazepine acetate-d<sub>4</sub>
  • HY-P2707
    α-Dendrotoxin
    		Inhibitor
    α-Dendrotoxin (α-DTX) is a voltage-gated K+ channel blocker and an acid-sensing ion channel (ASIC) inhibitor. α-Dendrotoxin blocks Kv1.1, Kv1.2, Kv1.6 and D-type (ID) voltage-gated K+ channels, and reversibly inhibits slowly inactivating potassium currents. α-Dendrotoxin induces epilepsy-related behaviors in mice. α-Dendrotoxin can be used in studies related to tonic-clonic seizures.
    α-Dendrotoxin
  • HY-P1218A
    Phrixotoxin 3 TFA
    		Inhibitor
    Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current.
    Phrixotoxin 3 TFA
  • HY-B1430R
    Butamben (Standard)
    		Inhibitor
    Butamben (Standard) is the analytical standard of Butamben. This product is intended for research and analytical applications. Butamben (Butyl 4-aminobenzoate) results in long-lasting relief from pain, without impairing motor function or other sensory functions.
    Butamben (Standard)
  • HY-160592
    Nav1.8-IN-11
    		Inhibitor
    Nav1.8-IN-11 (Example 1) is a Nav1.8 channel inhibitor with a IC50 value of 0.1 nM. Nav1.8-IN-11 can be used in the study of pain disorders.
    Nav1.8-IN-11
  • HY-10672
    Urotensin-II receptor antagonist-1
    		Inhibitor
    Urotensin-II receptor antagonist-1 (compound 1) is a low oral bioavailability (F=0-3%, rat) selective human Urotensin II receptor antagonist, Ki=16 nM (test on HEK293 cells expressing recombinant human UT receptor). Urotensin-II receptor antagonist-1 inhibits cytochrome P450 (IC50=0.75 μM, CYP2D6; 1.4 μM, CYP3A4), inhibits κ-opioid receptor (EC50=3.2 μM), targets cardiac sodium channels (Ki=2.5 μM).
    Urotensin-II receptor antagonist-1
  • HY-118050
    L589420-0-2
    		Inhibitor
    L589420-0-2 (L-420) is a sodium pump inhibitor with inhibitory activity in human erythrocytes. L589420-0-2 can regulate the concentration of intracellular sodium ions, thereby affecting the electrophysiological properties of cells. L589420-0-2 may also play an important role in the inhibition of cardiovascular diseases.
    L589420-0-2
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.